Liz Cramer

All things #oncology #biomarkers #genomics #pathology #precisionmedicine #womeninleadership Not med advice.

[Liz Cramer @oncELLEogy]

If you aren't following any #pathologists on twitter you're missing out on some of the best #healthcare tweets around. 🔬 #pathology

[Cure GI Cancers @RueschCenter]

Testing for MRD in Colorectal Cancer. @marshalj23, @benweinbergmd, @pashtoonkasi, and Stacey Cohen, MD, discuss the timing and frequency of MRD testing in patients with #CRC. https://t.co/7zjwu7xeyn via @onclive

[Oncology Brothers @OncBrothers]

This is the updated #Algorithm for #BladderCancer. Nivo/Gem/Cis was not approved at the time of this discussion w/ @DrKarineTawagi and @siadaneshmand but has been incorporated in this is mage below.

#OncTwitter #MedTwtitter #gusm #MedEd @CancerNetwrk #OncEd

[Pashtoon Kasi MD, MS @pashtoonkasi]

We grossly underestimate how quickly #immunotherapy can work. Especially with BOT/BAL (botensilimab) in our NEST🪺trial we are seeing💡#ctDNA decline📉 & CLEAR➕➡️➖within days to 2-4 weeks. Unprecedented!

📆March is #ColorectalCancerAwarenessMonth

https://t.co/zQSWQUMFxH

[Liz Cramer @oncELLEogy]

#USCAP2024 STILL TRUE! #pathology @TheUSCAP @pathologistmag @AMPath

[Liz Cramer @oncELLEogy]

If you aren't following any #pathologists on twitter you're missing out on some of the best #healthcare tweets around. 🔬 #pathology

[Liz Cramer @oncELLEogy]

Bespoke ctDNA testing for every patient to assess margins post-surgically and detect recurrence. Add power to your radiographic scans with Signatera testing: Come learn more at #USCAP2024 #pathology #lablife #oncology @OncoSause @NateraOncology

[Liz Cramer @oncELLEogy]

Emphasis on addressing health equity specifically related to patient accessibility and comprehension of biomarkers. @RuthHe12 shared exciting info on a cholangio specific initiative at @LombardiCancer @RueschCenter

[Liz Cramer @oncELLEogy]

“We use these technologies in partnership with you [patients]” @marshalj23 discussing importance of exploring different biomarker testing options at @RueschCenter patient symposium. @LombardiCancer #crcsm

[Liz Cramer @oncELLEogy]

This was such a fabulous talk - very thought provoking #crcsm

[Cure GI Cancers @RueschCenter]

Mario Giannakis, MD, Ph.D. of @DanaFarber, discusses "Features of Dietary -Induced Colorectal Carcinogenesis and Precision Prevention." during the #RueschSymposium. Join us live- to view this presentation. https://t.co/orlgap03uG @LombardiCancer

[Cure GI Cancers @RueschCenter]

Mario Giannakis, MD, Ph.D. of @DanaFarber, discusses "Features of Dietary -Induced Colorectal Carcinogenesis and Precision Prevention." during the #RueschSymposium. Join us live- to view this presentation. https://t.co/orlgap03uG @LombardiCancer

[Cure GI Cancers @RueschCenter]

Dr. John L. Marshall kicks off the GI Cancer Patient Symposium. We are excited to welcome GI Cancer patients, caregivers, survivors, and advocates to this exciting program. @marshalj23 @LombardiCancer @GICAlliance.

[Liz Cramer @oncELLEogy]

A completely packed 3rd day of @RueschCenter Annual Synposium! Today is patient symposium. These are the patients we wake up every day to support, #crcsm #oncology @mnoel3232 is answering questions about access to clinical trials. @LombardiCancer

[Johnathan Ebben MD, PhD @JohnEbbenMDPhD]

@TumorBoardTues @dradityabardia @ArielleMedford @stolaney1 @PTarantinoMD @TNBCFoundation @JaniceTNBCmets @BreastCaupdates @MPishvaian @hoperugo @IlanaSchlam @drsarahsam @ErikaHamilton9 @drteplinsky @brian_rini @katy_beckermann @Dr_Doc_ @z_veitch @matteolambe @CarmenCalfa @ferguskeane2 @ElizSMcKenna @zen228 @gasingiltv @OPENoncology @DocOnco @TaliLev123 @DrBaileeSliker @triparnasen @eskazanae @kevinpunie @BianchiniGP @AMJohnston1315 @patricia_stoop @HeatherMoore16 @genperisi @nursekristinrn @MGHBreastOnc @DrAmyComander @NCCH_MD @jennifermarksmd @ibrahimazaronc @DrR_DUNNE @DvirKathrin @ESchattner @oncELLEogy @PriscilaBCMD @KariWisinski_MD @marina_sharifi @meburkard There are lots of ways to connect with and participate in #TumorBoardTuesday--we ❤️ building new connections and continuing to grow the #oncology #meded community!

https://t.co/tQ6QuJU6bq

[Liz Cramer @oncELLEogy]

Paraphrase: “ctDNA as a binary vs continuous end point - so much potential and still more to learn, sampling time rigidity could limit the aggregation of data we need to understand nuances of different histologies.” #ClinicalTrials #biomarkers #oncology @CancerResrch

[Friends of Cancer Research @CancerResrch]

Starting now! Session 3: Regulatory Considerations for Using ctDNA as an Early Endpoint moderated by Amy McKee from @Parexel

Join live: https://t.co/iJRzOnD6fO

#ctDNAFriends

[Liz Cramer @oncELLEogy]

“Can we potentially get read out sooner by enriching high concept study pt population and confidence in evidence driving decisions with incorporation of ctDNA” #ClinicalTrials #biomarkers @CancerResrch @FoundationATCG @AstraZenecaUS @FDAOncology

[Liz Cramer @oncELLEogy]

Pt w/out measurable disease via RECIST often excluded from trial - discussion re:ctDNA & trial design that considers orthogonal patient populations (ctDNA-, disease measurable pts) and other thoughts prostate/breast w difficult to measure boney disease @CancerResrch @geoff_oxnard

[Liz Cramer @oncELLEogy]

Really interesting commentary on metrics + therapy (TKI vs IO) although a clear message that a reduction in ctDNA is associated with long term benefit. #oncology @Oncology_at_AZ Diana Vega’s very eloquent take home message for attendees. #biomarker

[Friends of Cancer Research @CancerResrch]

Starting now! Session 2: (ctMoniTR Module 1) moderated by Nevine Zariffa from NMD.

Join live: https://t.co/iJRzOnD6fO

#ctDNAFriends

[Liz Cramer @oncELLEogy]

“Do changes in ctDNA reflect response to TKI treatment” now we are diving in to dig in on the fabulous consortia work presented by @HillStirSci @NateraOncology @CancerResrch #oncology #biomarkers @FDAOncology

[Liz Cramer @oncELLEogy]

Appreciated the thoughtful commentary re: the need for fluidity in data (clinical, genomic, etc) because the purpose of ctDNA changes in real-time. Unique challenge to this #biomarker #oncology @TempusLabs @CancerResrch @PGDx_ @genentech

[Friends of Cancer Research @CancerResrch]

“I think we need to look at ctDNA research more holistically, otherwise we are going to miss key findings.” @TempusLabs's James Chen discussing the opportunities for ctDNA in #oncology.

https://t.co/iJRzOnD6fO

#ctDNAFriends

[Uzma Samadani @DrSamadani]

I finally got my face on the cover of ⁦@TheJNS⁩ ! (And every female neurosurgeon I know can say the same!)